Current Position, Affiliation
- Professor, University of Leicester & The John Walls Renal Unit, Leicester, UK
Education / Training
- 1992, M.D., University of Manchester, UK
- 2000, PhD., University of Leicester
Professional and Research Experience
- 2007 - Present, Professor, University of Leicester
Selected Publications
- Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2410316. PMID: 39453772
- Atrasentan in Patients with IgA Nephropathy. N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2409415. PMID: 39460694
- Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. Lancet. 2024 Mar 13:S0140-6736(23)02843-X. doi: 10.1016/S0140-6736(23)02843-X. PMID: 38492578
- Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023 Nov 2:S0140-6736(23)02302-4. doi: 10.1016/S0140-6736(23)02302-4. PMID: 37931634
- Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. PMID: 37591292
Plenary Lecture 2
Role
Speaker
Date & Time
12/05 15:10 - 16:00
Place
Room 1 ( 701A )
Lecture Title
The Rapidly Evolving Treatment Paradigm for IgA Nephropathy
KDIGO Session 1: IgAN Treatment Revolution in the Making: Targeting Both Drivers and Consequences of the Disease
Role
Speaker
Date & Time
12/05 16:25 - 16:45
Place
Room 1 ( 701A )
Lecture Title
Role of B Cell-targeted Therapies in the Management of IgAN
Sponsored by Vera Therapeutics - Emerging Therapies for IgA Nephropathy: Targeting BAFF and APRIL with Atacicept
Role
Speaker
Date & Time
12/05 12:45 - 13:00
Place
Room 2 ( 701B )
Lecture Title
Targeting BAFF and APRIL with Atacicept
IgA Nephropathy
Role
Speaker
Date & Time
12/06 11:55 - 12:10
Place
Room 4 ( 701EF )
Lecture Title
Future Clinical Trials in IgA Nephropathy
Oral Communications 5: Glomerular Diseases (GN)
Role
Speaker
Date & Time
12/06 10:06 - 10:15
Place
Room 8 ( 602 )
Lecture Title
Evaluation of Hematuria in Patients Treated With Ravulizumab in The Phase 2 SANCTUARY Trial
Oral Communications 5: Glomerular Diseases (GN)
Role
Speaker
Date & Time
12/06 10:51 - 11:00
Place
Room 8 ( 602 )
Lecture Title
Change in Soluble Biomarker Levels in Patients With IgA Nephropathy: An Analysis of The Phase 2 Trial of Ravulizumab (SANCTUARY)
Sponsored by Everest Medicines
Role
Speaker
Date & Time
12/07 12:30 - 13:30
Place
Room 2 ( 701B )
Lecture Title
Why Target the Gut to Treat the Kidneys? A New Treatment Paradigm for IgA Nephropathy
Meet the Professors
Role
Speaker
Date & Time
12/07 10:55 - 12:25
Place
Room 4 ( 701EF )
Lecture Title
Meet the Professors